TY - JOUR
T1 - Gynecologic Cancer InterGroup (GCIG) consensus review for carcinoid tumors of the ovary
AU - Reed, Nicholas S imon
AU - Gomez-Garcia, Eva
AU - Gallardo-Rincon, Dolores
AU - Barrette, Brigitte
AU - Baumann, Klaus
AU - Friedlander, Michael
AU - Kichenadasse, Ganessan
AU - Kim, Jae Weon
AU - Lorusso, Domenica
AU - Mirza, Mansoor R aza
AU - Ray-Coquard, Isabelle
PY - 2014/11/1
Y1 - 2014/11/1
N2 - Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms most commonly occurring in the gastrointestinal tract or the lungs. More frequent are gastrointestinal tumors, but over the past 30 years, there have been a number of small series or anecdotal case reports on ovarian NETs. Neuroendocrine tumors in the gynecologic tract are uncommon and account for about 2% of all gynecologic malignancies but may also be metastatic from other sites. They require a multimodality therapeutic approach determined by the extent of disease and the primary organ of involvement. Pathological diagnosis is critical to guide therapy. Surgery is the cornerstone of treatment for localized disease. There have been many new developments for treatment of advanced NETs including somatostatin analogs, hepatic artery embolization, chemotherapy, interferons, mammalian target of rapamycin inhibitors and radiolabeled somatostatin analogs. Given the rarity and lack of level I evidence, this is by nature more of a guidance and recommendation for management of these rare tumors until we can mount international studies.
AB - Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms most commonly occurring in the gastrointestinal tract or the lungs. More frequent are gastrointestinal tumors, but over the past 30 years, there have been a number of small series or anecdotal case reports on ovarian NETs. Neuroendocrine tumors in the gynecologic tract are uncommon and account for about 2% of all gynecologic malignancies but may also be metastatic from other sites. They require a multimodality therapeutic approach determined by the extent of disease and the primary organ of involvement. Pathological diagnosis is critical to guide therapy. Surgery is the cornerstone of treatment for localized disease. There have been many new developments for treatment of advanced NETs including somatostatin analogs, hepatic artery embolization, chemotherapy, interferons, mammalian target of rapamycin inhibitors and radiolabeled somatostatin analogs. Given the rarity and lack of level I evidence, this is by nature more of a guidance and recommendation for management of these rare tumors until we can mount international studies.
UR - http://www.scopus.com/inward/record.url?scp=84936126676&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84936126676&partnerID=8YFLogxK
U2 - 10.1097/IGC.0000000000000265
DO - 10.1097/IGC.0000000000000265
M3 - Article
C2 - 25341578
AN - SCOPUS:84936126676
VL - 24
SP - S35-S41
JO - International Journal of Gynecological Cancer
JF - International Journal of Gynecological Cancer
SN - 1048-891X
IS - 9
ER -